Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Sulforaphane for Major Depressive Disorder
NCT04246905Phase 2Unknown
- Sponsor
- Central South University
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sulforaphane in major depressive disorder (MDD), sponsored by Central South University. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Status: unknown.
02
Drugs
sulforaphane
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04246905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246905.